Acute neurotoxicity after yohimbine ingestion by a body builder

Clinical Toxicology

Volumn 47, Issue 8, 2009, Pages 827-829

  Giampreti, Andrea ^d   Lonati, Davide ^a   Locatelli, Carlo ^a   Rocchi, Loretta ^b   Campailla, Maria Teresa ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^d NONE

Author keywords

Acute poisoning; Dietary supplement; Overdose; Plasmatic dosage; Toxicokinetics

Indexed keywords

ACTIVATED CARBON; BENZODIAZEPINE DERIVATIVE; CLONIDINE; FUROSEMIDE; LABETALOL; LAXATIVE; URAPIDIL; YOHIMBINE;

ADULT; ARTICLE; BODY BUILDING; CASE REPORT; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; ENDOTRACHEAL INTUBATION; GLASGOW COMA SCALE; HALF LIFE TIME; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MALAISE; MALE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; SEIZURE; TACHYCARDIA; VITAL SIGN; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; COMBINED MODALITY THERAPY; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROTOXICITY SYNDROMES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT LIFTING; YOHIMBINE;

CORYNANTHE;

EID: 70350378796     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650903081601     Document Type: Article

References (14)

1. Shannon M, Neuman MI. Yohimbine. Pediatr Emerg Care 2000; 16:49-50.
2. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 2001; 91:215-243.
3. Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A. The pharmacokinetics of Yohimbine in man. Eur J Clin Pharmacol 1987; 32:577-582.
4. Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR. Dose dependent effects of Yohimbine on methadone maintained patients. Am J Drug Alcohol Abuse 1997; 23:327-333.
5. Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med 1985; 14:1002-1004.
6. Morales A, Surridge DH, Marshall PG, Fenemore J. Nonhormonal pharmacological treatment of organic impotence. J Urol 1982; 128:45-47.
7. Tu NN, Haller CA, Kearney TE. Yohimbine adverse drug events [abstract]. Clin Toxicol 2007; 45:625.
8. Grunewald KK, Bailey RS. Commercially marketed supplements for body building athletes. Sports Med 1993; 15:90-103.
9. Halcomb SE, Parab S, Ravikumar PR, Hoffman RS, Nelson LS. Massive Yohimbine overdose associated with sodium channel blockade [abstract]. Clin Toxicol 2006; 44:731.
10. Friesen K, Palatnick W, Tenenbein M. Benign course after massive Yohimbine ingestion. J Emerg Med 1993; 11:287-288.
11. Varkey S. Overdose of Yohimbine. Br Med J 1992; 304:548.
12. Vulto AG, de Smet PAGM. Drugs used in non-orthodox medicine. In: MNG Dukes, ed. Meyler's Side Effects of Drugs. 11th ed. Amsterdam: Elsevier; 1988:1024-1028.
13. Le Corre P, Dollo G, Chevanne F, Le Verge R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci 1999; 9:79-84.
14. Sturgill MG, Grasing KW, Rosen RC, Thomas TJ, Kulkarni GD, Trout JR, Maines M, Seibold JR. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol 1997; 29:697-703.